RxREVU, the leader in Prescription Decision Support, has partnered with the Mental Health Center of Denver to combat inefficiencies with behavioral health prescribing. Determining the most effective medication for a patient is challenging given the large number of alternatives available, but can be guided with pharmacogenomic tests that provide personalization for potential therapies. Pharmacogenomics is the study of how your genes affect your body’s response to and metabolism of medications. The partnership will seek to improve patient outcomes and lower costs for the health system by developing new Prescription Decision Support tools for behavioral healthcare.
RxREVU and the Mental Health Center of Denver are engaging in a collaborative project focused on cost management and pharmacogenomics for mental health prescribing. Both parties will collectively create an initial clinical and informatics design for a mental health prescribing module for RxREVU’s RxCheck Prescription Decision Support platform, and an economic framework for scaling the product to other health systems facing similar challenges. RxCheck will be integrated within the Netsmart Avatar electronic health record (EHR) – an electronic health system solution used by many mental and behavioral health providers.
“Today’s pharmacogenomic information is revolutionizing the way providers prescribe mental and behavioral medications. However, it is often challenging to interpret to make actionable insights for patients that can improve care. With the RxCheck platform, we now will have a simple way to interpret those results, integrated into the clinical workflow. We are optimistic this will lead to better outcomes at lower costs” said Carl Clark, MD, president and CEO of the Mental Health Center of Denver.
RxREVU is building functionality within the RxCheck platform to respond to triggers within standard provider workflow with medication recommendations based upon the Mental Health Center of Denver’s best practices, payer data, and gene-drug interactions fueled by pharmacogenomic reports. Pharmacogenomic data for prescribing in behavioral healthcare is increasing in prevalence due to its effectiveness in identifying medications that would otherwise result in costly and unfavorable side effects, readmissions, and poor adherence. RxREVU and Mental Health Center of Denver aim to make this data actionable in a new way, prior to a medication ordering decision in the provider’s workflow.
“Patients often cycle through several ineffective medications and dosages, struggling to find something that alleviates their symptoms. Using genetic testing to reduce the time it takes for a patient to find an effective medication is valuable work.” said Carm Huntress, CEO of RxREVU.
ABOUT RXREVU
RxREVU is a physician-founded leader in Prescription Decision Support. RxREVU’s cloud-based RxCheck™ PDS platform is a first-of-its-kind tool that provides guidance for prescribers upstream of ordering, leveraging standard tools within the EHR. With RxCheck™, prescribers are presented with a patient-centered view of what’s relevant for that prescribing choice, including trial adjudicated cost and medication adherence scores, and alerts that are aligned with relevant clinical protocols and CDS information (such as Drug to Drug and Drug to Allergy data). RxCheck ™enables hard-wired communication at the point of care, to inform physicians, drive consistent prescribing, lower costs, inform adherence, and improve quality metrics for HEDIS and Stars.
About Mental Health Center of Denver
The Mental Health Center of Denver is a private, not-for-profit community mental health center that primarily serves the residents of the City and County of Denver. We work to improve well-being in our community through a focus on recovery and resilience across the lifespan by providing a comprehensive range of community-based mental and behavioral health services to children, families and adults. The Mental Health Center of Denver is the national leader in redefining the way mental health is addressed in the community with innovative programs such as community impact projects, research and development, progressive housing solutions and comprehensive rehabilitation services. Last year, we provided treatment, prevention, outreach and crisis services to more than 44,000 children, families and adults in Denver. For more information, please visit www.mhcd.org.
Media Contact: Susan Francisco, RxREVU, 800.360.4965, Susan.Francisco@rxrevu.com
